Angioi Andrea, Cabiddu Gianfranca, Conti Maura, Pili Gianfranco, Atzeni Alice, Matta Valeria, Cao Riccardo, Floris Matteo, Songini Marco, Mulas Maria Franca, Rosner Mitchell, Pani Antonello
Division of Nephrology and Dialysis, Azienda Ospedaliera G. Brotzu, Piazzale Ricchi n°1, 09134, Cagliari, Italy.
Diabetology Unit, Azienda Ospedaliera G. Brotzu, Cagliari, Italy.
BMC Nephrol. 2018 Apr 2;19(1):77. doi: 10.1186/s12882-018-0875-8.
Metformin associated lactic acidosis (MALA) is a well-known serious side effect of biguanides. However, the best treatment strategy remains a matter of debate. In the last 14 years, we observed a significant increase in hospitalizations for MALA to our Center. We report the outcomes of our clinical and therapeutic approach.
This is a single-center case series. Twenty-eight patients affected with MALA and acute kidney failure admitted between January 2000 and September 2014 were included. We analyzed comorbidities, laboratory tests and clinical parameters at admission, at 36 h and at discharge. All patients were treated with sustained low-efficiency dialysis (SLED) until normalization of serum lactate (≤ 3 mmol/L), bicarbonate (between 20 and 25 mmol/L) and potassium (between 4.0 and 5.1 mmol/L).
The mortality rate was 21.4%, with all of the events occurring within 24 h from admission, and before or during the first hemodialysis treatment. Precipitating causes included; acute dehydration (86.4%), systemic inflammatory response syndrome (SIRS) (57.1%), sepsis (10.7%), nephrolithiasis (14.6%) and exposure to iodinated contrast (7.1%). No further episodes of lactic acidosis were described after discontinuing the drug over a mean follow-up of 27.2 months. Furthermore, while in 2010, we had a peak incidence of MALA of 76.8 cases per 100,000 patients on metformin, this rate fell after an education campaign conducted by specialists on the proper usage of metformin in patients at risk of MALA. Although the fall in incidence after the educational program was not necessarily causal, in 2014 the incidence was 32.9/100,000.
We report an improved mortality rate in patients affected with MALA and acute kidney injury treated with SLED compared with other series published in literature. Rapid introduction of effective hemodialysis is critical in improving outcomes.
二甲双胍相关乳酸酸中毒(MALA)是双胍类药物一种众所周知的严重副作用。然而,最佳治疗策略仍存在争议。在过去14年中,我们中心因MALA住院的人数显著增加。我们报告了我们的临床和治疗方法的结果。
这是一个单中心病例系列。纳入了2000年1月至2014年9月期间收治的28例患有MALA和急性肾衰竭的患者。我们分析了入院时、36小时时和出院时的合并症、实验室检查和临床参数。所有患者均接受持续低效透析(SLED)治疗,直至血清乳酸(≤3 mmol/L)、碳酸氢盐(20至25 mmol/L)和钾(4.0至5.1 mmol/L)恢复正常。
死亡率为21.4%,所有死亡事件均发生在入院后24小时内,以及首次血液透析治疗前或治疗期间。诱发原因包括:急性脱水(86.4%)、全身炎症反应综合征(SIRS)(57.1%)、脓毒症(10.7%)、肾结石(14.6%)和接触碘造影剂(7.1%)。在平均27.2个月的随访期内停药后,未再出现乳酸酸中毒发作。此外,2010年,我们中心使用二甲双胍的患者中MALA的发病率达到峰值,为每10万人76.8例,在专家针对有MALA风险的患者进行二甲双胍正确使用的教育活动后,这一发病率有所下降。尽管教育项目实施后发病率下降不一定存在因果关系,但2014年发病率为32.9/10万。
我们报告称,与文献中发表的其他系列研究相比,接受SLED治疗的MALA和急性肾损伤患者的死亡率有所改善。迅速引入有效的血液透析对改善预后至关重要。